Support from readers like you keeps The Journal open.
You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.
If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.
TDS ARE OFF on their holidays today due to the Dáil rising for the summer.
Senators have to wait for another week before they can head off, as they are due to sit for another week.
The Taoiseach was asked yesterday if politicians should abandon the idea of a two-month break, and just take the usual two-week holiday, like everybody else.
He told reporters that he understands there is a “perception” among the public that politicians don’t work over the summer, but he said this is not true.
Advertisement
“I can certainly guarantee that no TD will be taking a two-month break,” he said, adding that there is “a big difference between the Dáil being in recess and the Dáil being on holidays”.
He said ministers will be busy in their departments, while TDs will be “very busy” catching up with their constituency work.
The Taoiseach said Cabinet will continue to meet over the next couple of weeks.
A second Cabinet meeting of the week is due to be held tomorrow in order to clear the decks ahead of the autumn session.
A special Cabinet meeting is also due to be held in Derrynane in Kerry next Wednesday, with a third Cabinet meeting due to be held the following week.
Varadkar said he will also be travelling to several European capitals on business over the summer.
Readers like you are keeping these stories free for everyone...
A mix of advertising and supporting contributions helps keep paywalls away from valuable information like this article.
Over 5,000 readers like you have already stepped up and support us with a monthly payment or a once-off donation.
To embed this post, copy the code below on your site
Close
46 Comments
This is YOUR comments community. Stay civil, stay constructive, stay on topic.
Please familiarise yourself with our comments policy
here
before taking part.
@Jeff Nolan: there has been, that’s why instead of the recommended three to four week interval between doses it’s been extended to 12 weeks. Chief medical officers in the U.K. said vaccine shortages was main reason for the longer vaccine schedule.
@EillieEs: my understanding is that they have enough vaccine but they want to show how many people vaccinated statistics so they are giving it to double the amount of people first and second vaccinations much later. There have been no headlines in the uk of 60% reduction in vaccine for uk. All of their headlines say that the reduction is for the EU.
@Jeff Nolan: EU s main allegiance is to Pfizer who are making profits on vaccines. Astra Zenica is not for profit and is in fact prioritising India and other poor countries in conjunction with WHO.
@Tony Lyons: You are wrong. In trials they gave one dose followed by a half dose. Two doses have been found to be more effective and they are supplying this vaccine on the understanding that each person receives two doses. This is why there is a shortage in supply.
@EillieEs: That’s the Pfizer vaccine they are spreading out. I read that AstraZeneca is manufacturing the Oxford Vaccine in the UK for the UK market In Melbourne for the Australian market, India for that market & beyond because they have vast manufacturing capacity & Belgium & Holland for the EU. The EU should just ask for their money back from AstraZeneca if they feel let down & wait for Sanofi to whom they have placed orders for 300 million doses @ $10.50 a pop & lets not forget they haven’t even approved the Astra jab for emergency use yet ;-)
@Jeff Nolan: AZ had promised that they will deliver the original amount that was promised.. I o w there is no shortage but they wanted to deliver to other countries. There not to be trusted and the EU can better deal with Pfizer from now on.
@Joe Thorpe: BBC reporting has been hilarious. When things are going well it’s “Oxford AstraZenica”, all of a sudden it’s “The AstraZenica vaccine – with research from Oxford university”. Shpinnnnn.
Let’s hope the Johnson and Johnson vaccine is soon approved by the US and the EU shortly after. It only requires one jab, and does not require the same storage requirements of the Pfizer vaccine. This vaccine will be the game changer.
@Teresa O’Halloran: yeah but it has lower efficiency so should probably be used on the younger people in society and use the others for the more vulnerable
I’d rather the vaccine production to be carried out properly without undue pressure, this kind of rhetoric from EU leaders may lead to shortcuts being taken, dangerous game.
@Mark Malone: how would you propose pushing the pharmaceutical companies to adhere to their contracts so, particularly if money was paid up front to allow production capacity to be increased? You can’t expect the EU to be jumping up and down with joy instead
@Mark Malone: shame on the EU leaders for standing up for its citizens after AZ happily took the tax payers’ money to upgrade their production and meet the demands as per the contract and failed to do so.
@David Van-Standen: scaling up product from lab or clinic scale to commercial scale isn’t easy and can face a number of unforseen setbacks and issues that often aren’t seen until the first batch is made. Any number of things, be it the chemistry when moving to plant scale produces lower expected yields, supplier issues due to Brexit, validation issues, material impurity causing issues with quality, process deviations, quality control issues, plant workers/automation software over/under charging a vessel/reactor with too much of a solvent or chemical in error damaging a batch, engineering issues, the list goes on.
No doubt the hundreds of talented people working tirelessly to get this product made safely, compliantly and within the time frame the top brass promised is commendable.
@Derek: except that’s not what the EU seems to think. That would be a satisfactory response from the company. The EU says the response from the company was not satisfactory. It doesn’t take much reading between the lines to work this out: the EU thinks it’s not getting what it paid for and therefore some other country or countries are.
@Derek: Quality and safety would always be number 1 but if that were the case why were AZ not communicating with the e.u on the issue from the outset and all the way through the process
I can understand from a validation point of view in that unforeseen issues can occur with mass production but again the e.u are right as the answers are unacceptable especially after pumping in billions to ramp it up and as a customer they have the right to know why AZ have not adhered to their contract
@Mark Malone: Reading between the lines it seems the EU are not buying the “production issues” excuse and are of the opinion that the vaccines are actually being produced in quantity but are promised to higher bidders. Think back to the early days of the pandemic and all the issues around PPE supplies. Cargo plane pilots with stories about EU bound PPE cargos about to be loaded on their planes but then vans turning up full of US dollars and the cargo being switched to US bound flights. America was basically paying cargo handlers to steal the supplies.
@James Grant: The EU may have pumped billions into the vaccine race but they didn’t pump billions into AstraZeneca they simply paid up front for the lowest priced candidate. Production for the EU deliveries is being done inside the EU so i dare say if the EU goes at them AZ will in turn go after their producer in Belgium.
Apparently they are using the chemicals needed to produce orders for others who are paying more. It isn’t a simple production issue, they are selling the product to the highest bidder
@ChuckE: What really happened is the UK made an order and contract first then Germany, France, Italy and the Netherlands done the same a few weeks later calling it the vaccine alliance, the EU got upset and said it was their job then made them cancel the contract and the EU renegotiated the contract which took over 2 months putting them further back in a que but they want it now, the other problem is the EU still have not approved the vaccine.
So the EU wants to bully a company whose product it still hasn’t approved for use. The EU bureaucracy has publicly raised doubts about this vaccine when the UK authorised it’s use and then delayed approval while other countries began to use it. Like any company supply to its customers with existing supply chains in place will get priority. It’s no use the EU trying to make Astra Zeneca the bad guys – it’s the EU that has shown incredible incompetence.
@Sara Davis: only U.K. and India are using it. It looks like Europe’s manufactured doses which have been paid for went to the U.K., hence the suggestion today that vaccines manufactured in Europe stay in Europe
This NOW is what sovereignity is all about. Germany has bought direct so did UK and neither flouted or broke any eu law which allow member states to do that in c are of emergency but apparently the commission objected to govt here getting supplies from elsewhere , UK , and govt obeys and what is TD doing they are not holding govt to account to the DAIL and their constituents,
There is absolutely no way that rich connected folk are paying these very reputable (cough) companies over the odds to jump the queue. No way that’s happening at all.
To a large degree ‘Big Pharma’ appears to have the EU over the proverbial barrel on this one and both sides know it. I see this as simply the EU grandstanding for public consumption full well knowing there’s very little they can do to improve the situation. It looks good in the media though…
Another cost of membership or more cost of the loan to ireland and the treaty that commission can hold over govt head NOT APPROVED BY DAIL until loan paid back that control sulloy of vacine to the Irish people . Hw do we know , cos we dont , what type of deal made between commission and suppliers , We dont even know and will never know f the are paid and enif money in the eu to do it ? Nor do we know how much eu is charging us for it ? And dail to whom govt account . ZERO
@Eugene Norman: Grow up and learn. By god u have not a clue what u are talking about. The European Stability Mechanism Treaty make the austerity terms of the loan to ireland the Irish people an international agreement made by M Noonan and the head of the Euro Area States by which M Noonan Agreed that the EU Commission will monitor performance of the terms until the loan is paid back . Not one cent of principal is paid back . Beliieve u me man believe u me U are paying and paying big for membership of the EU. It is becoming a very very expensive e club. As i said even under eu law a member state can buy direct a vacine if there is an emergency. The UK did it . Germany is doing it . The commission said no to the govt doing it . The govt is towing the line . Do u really think our minister are going to do that unless they were afraid of a more powerful lever bing pulled and it is that loan . That treaty not ratified by dail .
@Mary Ward: EU agreed substantial discounts on vaccine prices which any single country would not be able negotiate on their own. So that could be the cause for pharma companies delay shipping to EU and they want to verify
Why wasn’t this emergency approved by Ireland at the beginning of January and we could have got some stock in? We can’t stand up for ourselves and do what the commission tells us. The EMA was taking so long to approve the vaccine that Astra Zeneca probably got fed up waiting and sold it to other countries
This vaccine appears to be the game changer in terms of ramping up the programme. Will be interesting to see how this affects the rollout of the programme but I fear it could lead to significant delays well past the “September” target. A serious blow
Good luck with that. Most of the vaccine is made in the UK with India likely to play a huge role as I understand it.
The EU had no issue burying developing countries when it along with 4 other countries bought up half the vaccine supply for 2021 (for approx 13% of the world population) and ordered less than was needed (even now about half as many doses per person as UK and Canada) so I have zero sympathy.
The pfizer vaccine has about 50-55% efficacy after dose 1 and can increase to about 94% after 2nd dose. Some studies in israel (ref BMJ) put pfizer vac as little as 33% efficacy after dose 1. The moderna vaccine has approx 70% efficacy after 1 dose increasing to +94% after second dose. Astra zenica is hard to find evidence on efficacy but allegedly provides 70% after 2 doses. But ongoing studies suggest it could be as high as 90% All these vaccines are 2 shot vaccines whereas the Johnson & Johnson vaccine provides 70% with just one dose. So all in all i believe its more of an economic strategy. I could be wrong!! There are many other vaccines on the market these days that have a low efficacy. The shingles vaccine being one. Only a 55 – 65% efficacy.
The vaccine does not need to be approved for administration to ensure delivery. AZ are contractually obliged to deliver the agreed amount of doses in the set time frame. Failure to do so should see the EU throw the legal book at them. It has been paid for up front approved for use or not.
What really happened is the UK made an order and contract first then Germany, France, Italy and the Netherlands done the same a few weeks later calling it the vaccine alliance, the EU got upset and said it was their job then made them cancel the contract and the EU renegotiated the contract which took over 2 months putting them further back in a que but they want it now, the other problem is the EU still have not approved the vaccine.
Explainer: What is a tariff and why has Trump just slapped a 20% one on EU goods?
Updated
7 hrs ago
35.3k
121
Live Blog
Trump hits EU goods with 20% tariff and rails against foreigners 'pillaging' US
Updated
6 hrs ago
107k
199
Live Blog
Trump hits EU goods with 20% tariff and rails against foreigners 'pillaging' US
Updated
6 hrs ago
107k
199
Your Cookies. Your Choice.
Cookies help provide our news service while also enabling the advertising needed to fund this work.
We categorise cookies as Necessary, Performance (used to analyse the site performance) and Targeting (used to target advertising which helps us keep this service free).
We and our 161 partners store and access personal data, like browsing data or unique identifiers, on your device. Selecting Accept All enables tracking technologies to support the purposes shown under we and our partners process data to provide. If trackers are disabled, some content and ads you see may not be as relevant to you. You can resurface this menu to change your choices or withdraw consent at any time by clicking the Cookie Preferences link on the bottom of the webpage .Your choices will have effect within our Website. For more details, refer to our Privacy Policy.
We and our vendors process data for the following purposes:
Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a device. Personalised advertising and content, advertising and content measurement, audience research and services development.
Cookies Preference Centre
We process your data to deliver content or advertisements and measure the delivery of such content or advertisements to extract insights about our website. We share this information with our partners on the basis of consent. You may exercise your right to consent, based on a specific purpose below or at a partner level in the link under each purpose. Some vendors may process your data based on their legitimate interests, which does not require your consent. You cannot object to tracking technologies placed to ensure security, prevent fraud, fix errors, or deliver and present advertising and content, and precise geolocation data and active scanning of device characteristics for identification may be used to support this purpose. This exception does not apply to targeted advertising. These choices will be signaled to our vendors participating in the Transparency and Consent Framework.
Manage Consent Preferences
Necessary Cookies
Always Active
These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work.
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may be used by those companies to build a profile of your interests and show you relevant adverts on other sites. They do not store directly personal information, but are based on uniquely identifying your browser and internet device. If you do not allow these cookies, you will experience less targeted advertising.
Functional Cookies
These cookies enable the website to provide enhanced functionality and personalisation. They may be set by us or by third party providers whose services we have added to our pages. If you do not allow these cookies then these services may not function properly.
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not be able to monitor our performance.
Store and/or access information on a device 110 partners can use this purpose
Cookies, device or similar online identifiers (e.g. login-based identifiers, randomly assigned identifiers, network based identifiers) together with other information (e.g. browser type and information, language, screen size, supported technologies etc.) can be stored or read on your device to recognise it each time it connects to an app or to a website, for one or several of the purposes presented here.
Personalised advertising and content, advertising and content measurement, audience research and services development 143 partners can use this purpose
Use limited data to select advertising 113 partners can use this purpose
Advertising presented to you on this service can be based on limited data, such as the website or app you are using, your non-precise location, your device type or which content you are (or have been) interacting with (for example, to limit the number of times an ad is presented to you).
Create profiles for personalised advertising 83 partners can use this purpose
Information about your activity on this service (such as forms you submit, content you look at) can be stored and combined with other information about you (for example, information from your previous activity on this service and other websites or apps) or similar users. This is then used to build or improve a profile about you (that might include possible interests and personal aspects). Your profile can be used (also later) to present advertising that appears more relevant based on your possible interests by this and other entities.
Use profiles to select personalised advertising 83 partners can use this purpose
Advertising presented to you on this service can be based on your advertising profiles, which can reflect your activity on this service or other websites or apps (like the forms you submit, content you look at), possible interests and personal aspects.
Create profiles to personalise content 39 partners can use this purpose
Information about your activity on this service (for instance, forms you submit, non-advertising content you look at) can be stored and combined with other information about you (such as your previous activity on this service or other websites or apps) or similar users. This is then used to build or improve a profile about you (which might for example include possible interests and personal aspects). Your profile can be used (also later) to present content that appears more relevant based on your possible interests, such as by adapting the order in which content is shown to you, so that it is even easier for you to find content that matches your interests.
Use profiles to select personalised content 35 partners can use this purpose
Content presented to you on this service can be based on your content personalisation profiles, which can reflect your activity on this or other services (for instance, the forms you submit, content you look at), possible interests and personal aspects. This can for example be used to adapt the order in which content is shown to you, so that it is even easier for you to find (non-advertising) content that matches your interests.
Measure advertising performance 134 partners can use this purpose
Information regarding which advertising is presented to you and how you interact with it can be used to determine how well an advert has worked for you or other users and whether the goals of the advertising were reached. For instance, whether you saw an ad, whether you clicked on it, whether it led you to buy a product or visit a website, etc. This is very helpful to understand the relevance of advertising campaigns.
Measure content performance 61 partners can use this purpose
Information regarding which content is presented to you and how you interact with it can be used to determine whether the (non-advertising) content e.g. reached its intended audience and matched your interests. For instance, whether you read an article, watch a video, listen to a podcast or look at a product description, how long you spent on this service and the web pages you visit etc. This is very helpful to understand the relevance of (non-advertising) content that is shown to you.
Understand audiences through statistics or combinations of data from different sources 74 partners can use this purpose
Reports can be generated based on the combination of data sets (like user profiles, statistics, market research, analytics data) regarding your interactions and those of other users with advertising or (non-advertising) content to identify common characteristics (for instance, to determine which target audiences are more receptive to an ad campaign or to certain contents).
Develop and improve services 83 partners can use this purpose
Information about your activity on this service, such as your interaction with ads or content, can be very helpful to improve products and services and to build new products and services based on user interactions, the type of audience, etc. This specific purpose does not include the development or improvement of user profiles and identifiers.
Use limited data to select content 37 partners can use this purpose
Content presented to you on this service can be based on limited data, such as the website or app you are using, your non-precise location, your device type, or which content you are (or have been) interacting with (for example, to limit the number of times a video or an article is presented to you).
Use precise geolocation data 46 partners can use this special feature
With your acceptance, your precise location (within a radius of less than 500 metres) may be used in support of the purposes explained in this notice.
Actively scan device characteristics for identification 27 partners can use this special feature
With your acceptance, certain characteristics specific to your device might be requested and used to distinguish it from other devices (such as the installed fonts or plugins, the resolution of your screen) in support of the purposes explained in this notice.
Ensure security, prevent and detect fraud, and fix errors 92 partners can use this special purpose
Always Active
Your data can be used to monitor for and prevent unusual and possibly fraudulent activity (for example, regarding advertising, ad clicks by bots), and ensure systems and processes work properly and securely. It can also be used to correct any problems you, the publisher or the advertiser may encounter in the delivery of content and ads and in your interaction with them.
Deliver and present advertising and content 99 partners can use this special purpose
Always Active
Certain information (like an IP address or device capabilities) is used to ensure the technical compatibility of the content or advertising, and to facilitate the transmission of the content or ad to your device.
Match and combine data from other data sources 72 partners can use this feature
Always Active
Information about your activity on this service may be matched and combined with other information relating to you and originating from various sources (for instance your activity on a separate online service, your use of a loyalty card in-store, or your answers to a survey), in support of the purposes explained in this notice.
Link different devices 53 partners can use this feature
Always Active
In support of the purposes explained in this notice, your device might be considered as likely linked to other devices that belong to you or your household (for instance because you are logged in to the same service on both your phone and your computer, or because you may use the same Internet connection on both devices).
Identify devices based on information transmitted automatically 88 partners can use this feature
Always Active
Your device might be distinguished from other devices based on information it automatically sends when accessing the Internet (for instance, the IP address of your Internet connection or the type of browser you are using) in support of the purposes exposed in this notice.
Save and communicate privacy choices 69 partners can use this special purpose
Always Active
The choices you make regarding the purposes and entities listed in this notice are saved and made available to those entities in the form of digital signals (such as a string of characters). This is necessary in order to enable both this service and those entities to respect such choices.
have your say